کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3935880 | 1253427 | 2011 | 5 صفحه PDF | دانلود رایگان |

ObjectiveTo compare the ovulation rate between raloxifene and clomiphene citrate (CC) in patients with polycystic ovary syndrome (PCOS).DesignDouble-blind, randomized, superiority clinical trial.SettingTertiary university hospital.Patient(s)Women with ovulatory dysfunction and PCOS based on the Rotterdam criteria.Intervention(s)One of two oral treatments: 5 days of 100 mg/day of CC or R.Main Outcome Measure(s)Ovulation, based on follicle collapse on serial ultrasound and midsecretory serum progesterone concentration (≥3 ng/dL).Result(s)The women with PCOS (n = 82) were randomized to receive CC (n = 40) or raloxifene (n = 42). From these, 68 patients finished the trial according to the protocol (CC: n = 37; raloxifene: n = 31). There were no statistically significant differences between the groups in ovulation rates per an intention-to-treat analysis based on ultrasound alone (CC: 21 of 40 vs. raloxifene: 17 of 42) or on progesterone levels (CC: 16 of 40 vs. raloxifene: 11 of 42). No serious adverse events were observed in either group.Conclusion(s)No statistically significant difference in ovulation was observed between raloxifene and clomiphene citrate in patients with PCOS with ovulatory dysfunction.
Journal: Fertility and Sterility - Volume 96, Issue 3, September 2011, Pages 769–773